Which has stronger earnings & valuation, GDRX or DLO?

DLocal has higher revenue and earnings than GoodRx. DLocal is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.19 $30.44M $0.06 46.00 DLocal $1.09B 3.31 $196.80M $0.63 19.50

Is GDRX or DLO more profitable?

DLocal has a net margin of 15.85% compared to GoodRx's net margin of 2.61%. DLocal's return on equity of 41.22% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.61% 7.90% 3.23% DLocal 15.85% 41.22% 14.27%

Which has better earnings & valuation, JOYY or GDRX?

JOYY has higher revenue and earnings than GoodRx. JOYY is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JOYY $2.12B 1.55 $2.10B $4.31 15.29 GoodRx $796.85M 1.19 $30.44M $0.06 46.00

Is JOYY or GDRX more profitable?

JOYY has a net margin of 10.42% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat JOYY's return on equity. Company Net Margins Return on Equity Return on Assets JOYY 10.42% 3.67% 3.20% GoodRx 2.61% 7.90% 3.23%

Does the media prefer JOYY or GDRX?

In the previous week, GoodRx had 1 more articles in the media than JOYY. MarketBeat recorded 2 mentions for GoodRx and 1 mentions for JOYY. GoodRx's average media sentiment score of 0.58 beat JOYY's score of 0.00 indicating that GoodRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment JOYY 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GoodRx 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, FOUR or GDRX?

Shift4 Payments has higher revenue and earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than Shift4 Payments, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shift4 Payments $4.18B 0.84 $119M $0.84 52.82 GoodRx $796.85M 1.19 $30.44M $0.06 46.00

Is FOUR or GDRX more profitable?

Shift4 Payments has a net margin of 2.63% compared to GoodRx's net margin of 2.61%. Shift4 Payments' return on equity of 33.55% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets Shift4 Payments 2.63% 33.55% 5.01% GoodRx 2.61% 7.90% 3.23%

Does the media favor FOUR or GDRX?

In the previous week, Shift4 Payments had 3 more articles in the media than GoodRx. MarketBeat recorded 5 mentions for Shift4 Payments and 2 mentions for GoodRx. Shift4 Payments' average media sentiment score of 1.35 beat GoodRx's score of 0.58 indicating that Shift4 Payments is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shift4 Payments 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, RNG or GDRX?

RingCentral has higher revenue and earnings than GoodRx. RingCentral is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RingCentral $2.52B 1.20 $43.39M $0.94 38.15 GoodRx $796.85M 1.19 $30.44M $0.06 46.00

Is RNG or GDRX more profitable?

RingCentral has a net margin of 3.31% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat RingCentral's return on equity. Company Net Margins Return on Equity Return on Assets RingCentral 3.31% -33.75% 12.40% GoodRx 2.61% 7.90% 3.23%

Does the media refer more to RNG or GDRX?

In the previous week, RingCentral had 5 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for RingCentral and 2 mentions for GoodRx. RingCentral's average media sentiment score of 1.04 beat GoodRx's score of 0.58 indicating that RingCentral is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RingCentral 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, FA or GDRX?

First Advantage has higher revenue and earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than First Advantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Advantage $1.61B 1.78 $37.29M $0.04 417.53 GoodRx $796.85M 1.19 $30.44M $0.06 46.00

GoodRx (GDRX) Competitors

$2.76 +0.09 (+3.37%)

Closing price 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 07:26 PM Eastern

Compare

GDRX vs. DLO, JOYY, FOUR, RNG, and FA

Should you buy GoodRx stock or one of its competitors? MarketBeat compares GoodRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GoodRx include DLocal (DLO), JOYY (JOYY), Shift4 Payments (FOUR), RingCentral (RNG), and First Advantage (FA). These companies are all part of the "business services" industry.

How does GoodRx compare to DLocal?

GoodRx (NASDAQ:GDRX) and DLocal (NASDAQ:DLO) are both business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

DLocal has higher revenue and earnings than GoodRx. DLocal is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.19	$30.44M	$0.06	46.00
DLocal	$1.09B	3.31	$196.80M	$0.63	19.50

63.8% of GoodRx shares are held by institutional investors. Comparatively, 90.1% of DLocal shares are held by institutional investors. 5.9% of GoodRx shares are held by insiders. Comparatively, 45.4% of DLocal shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GoodRx has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, DLocal has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

GoodRx currently has a consensus target price of $3.81, indicating a potential upside of 38.13%. DLocal has a consensus target price of $16.63, indicating a potential upside of 35.34%. Given GoodRx's higher possible upside, research analysts plainly believe GoodRx is more favorable than DLocal.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
DLocal	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

DLocal has a net margin of 15.85% compared to GoodRx's net margin of 2.61%. DLocal's return on equity of 41.22% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.61%	7.90%	3.23%
DLocal	15.85%	41.22%	14.27%

In the previous week, GoodRx had 2 more articles in the media than DLocal. MarketBeat recorded 2 mentions for GoodRx and 0 mentions for DLocal. GoodRx's average media sentiment score of 0.58 beat DLocal's score of 0.00 indicating that GoodRx is being referred to more favorably in the media.

Company	Overall Sentiment
GoodRx	Positive
DLocal	Neutral

Summary

DLocal beats GoodRx on 11 of the 16 factors compared between the two stocks.

How does GoodRx compare to JOYY?

JOYY (NASDAQ:JOYY) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

In the previous week, GoodRx had 1 more articles in the media than JOYY. MarketBeat recorded 2 mentions for GoodRx and 1 mentions for JOYY. GoodRx's average media sentiment score of 0.58 beat JOYY's score of 0.00 indicating that GoodRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JOYY	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GoodRx	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

JOYY has higher revenue and earnings than GoodRx. JOYY is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JOYY	$2.12B	1.55	$2.10B	$4.31	15.29
GoodRx	$796.85M	1.19	$30.44M	$0.06	46.00

JOYY currently has a consensus price target of $74.67, indicating a potential upside of 13.29%. GoodRx has a consensus price target of $3.81, indicating a potential upside of 38.13%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than JOYY.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JOYY	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

JOYY has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

JOYY has a net margin of 10.42% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat JOYY's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JOYY	10.42%	3.67%	3.20%
GoodRx	2.61%	7.90%	3.23%

36.8% of JOYY shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 43.0% of JOYY shares are owned by insiders. Comparatively, 5.9% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

GoodRx beats JOYY on 9 of the 16 factors compared between the two stocks.

How does GoodRx compare to Shift4 Payments?

Shift4 Payments (NYSE:FOUR) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

98.9% of Shift4 Payments shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 1.5% of Shift4 Payments shares are owned by insiders. Comparatively, 5.9% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Shift4 Payments has higher revenue and earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than Shift4 Payments, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shift4 Payments	$4.18B	0.84	$119M	$0.84	52.82
GoodRx	$796.85M	1.19	$30.44M	$0.06	46.00

Shift4 Payments presently has a consensus price target of $68.29, suggesting a potential upside of 53.91%. GoodRx has a consensus price target of $3.81, suggesting a potential upside of 38.13%. Given Shift4 Payments' stronger consensus rating and higher probable upside, equities research analysts plainly believe Shift4 Payments is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shift4 Payments	1 Sell rating(s)	12 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.39
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

Shift4 Payments has a net margin of 2.63% compared to GoodRx's net margin of 2.61%. Shift4 Payments' return on equity of 33.55% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shift4 Payments	2.63%	33.55%	5.01%
GoodRx	2.61%	7.90%	3.23%

In the previous week, Shift4 Payments had 3 more articles in the media than GoodRx. MarketBeat recorded 5 mentions for Shift4 Payments and 2 mentions for GoodRx. Shift4 Payments' average media sentiment score of 1.35 beat GoodRx's score of 0.58 indicating that Shift4 Payments is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shift4 Payments	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shift4 Payments has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Summary

Shift4 Payments beats GoodRx on 13 of the 16 factors compared between the two stocks.

How does GoodRx compare to RingCentral?

RingCentral (NYSE:RNG) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

In the previous week, RingCentral had 5 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for RingCentral and 2 mentions for GoodRx. RingCentral's average media sentiment score of 1.04 beat GoodRx's score of 0.58 indicating that RingCentral is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RingCentral	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of RingCentral shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 7.3% of RingCentral shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

RingCentral has higher revenue and earnings than GoodRx. RingCentral is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RingCentral	$2.52B	1.20	$43.39M	$0.94	38.15
GoodRx	$796.85M	1.19	$30.44M	$0.06	46.00

RingCentral has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

RingCentral currently has a consensus target price of $43.00, suggesting a potential upside of 19.92%. GoodRx has a consensus target price of $3.81, suggesting a potential upside of 38.13%. Given GoodRx's higher possible upside, analysts clearly believe GoodRx is more favorable than RingCentral.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RingCentral	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

RingCentral has a net margin of 3.31% compared to GoodRx's net margin of 2.61%. GoodRx's return on equity of 7.90% beat RingCentral's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RingCentral	3.31%	-33.75%	12.40%
GoodRx	2.61%	7.90%	3.23%

Summary

RingCentral beats GoodRx on 11 of the 16 factors compared between the two stocks.

How does GoodRx compare to First Advantage?

First Advantage (NYSE:FA) and GoodRx (NASDAQ:GDRX) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

First Advantage has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

GoodRx has a net margin of 2.61% compared to First Advantage's net margin of 0.65%. First Advantage's return on equity of 13.16% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Advantage	0.65%	13.16%	7.33%
GoodRx	2.61%	7.90%	3.23%

First Advantage presently has a consensus target price of $18.50, indicating a potential upside of 10.77%. GoodRx has a consensus target price of $3.81, indicating a potential upside of 38.13%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than First Advantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Advantage	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, GoodRx had 2 more articles in the media than First Advantage. MarketBeat recorded 2 mentions for GoodRx and 0 mentions for First Advantage. First Advantage's average media sentiment score of 1.80 beat GoodRx's score of 0.58 indicating that First Advantage is being referred to more favorably in the media.

Company	Overall Sentiment
First Advantage	Very Positive
GoodRx	Positive

First Advantage has higher revenue and earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than First Advantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Advantage	$1.61B	1.78	$37.29M	$0.04	417.53
GoodRx	$796.85M	1.19	$30.44M	$0.06	46.00

94.9% of First Advantage shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 4.4% of First Advantage shares are owned by insiders. Comparatively, 5.9% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

First Advantage beats GoodRx on 9 of the 16 factors compared between the two stocks.

Get GoodRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDRX vs. The Competition

Export

Metric	GoodRx	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$914.67M	$8.78B	$6.54B	$12.32B
Dividend Yield	N/A	1.72%	2.68%	5.88%
P/E Ratio	46.01	24.45	25.39	23.96
Price / Sales	1.19	16.68	530.17	107.90
Price / Cash	6.67	99.35	45.29	53.76
Price / Book	1.52	5.83	10.76	6.41
Net Income	$30.44M	$174.80M	$3.56B	$337.14M
7 Day Performance	5.75%	2.95%	1.37%	-0.48%
1 Month Performance	4.15%	4.43%	0.81%	0.49%
1 Year Performance	-45.56%	11.90%	30.53%	28.16%

GoodRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDRX GoodRx	4.0407 of 5 stars	$2.76 +3.4%	$3.81 +38.1%	-43.1%	$914.67M	$796.85M	46.01	950
DLO DLocal	4.7625 of 5 stars	$12.66 +3.3%	$16.63 +31.3%	+18.4%	$3.61B	$1.09B	20.10	1,274
JOYY JOYY	3.4429 of 5 stars	$68.85 +1.5%	$74.67 +8.4%	N/A	$3.39B	$2.12B	15.97	5,421
FOUR Shift4 Payments	4.739 of 5 stars	$39.94 -3.0%	$70.19 +75.7%	-58.7%	$3.27B	$4.18B	47.55	6,300	Positive News Analyst Forecast
RNG RingCentral	4.826 of 5 stars	$38.23 -1.1%	$43.00 +12.5%	+33.3%	$3.24B	$2.52B	40.67	7,378	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GoodRx (GDRX) Competitors